Background: The American College of Cardiology (ACC), American Heart Association (AHA) and other organizations announced a new hypertension guideline (2017 ACA/AHA Guideline) in November 2017. However, other organizations such as the European Society of Cardiology and European Society of Hypertension maintained their diagnostic thresholds. It is necessary to evaluate the effects of blood pressure (BP) and antihypertensive drugs on the probability of having heart disease (HD). Data and Methods: The effects of BP, antihypertensive drugs and other factors on the probability of undergoing HD treatment were analyzed. We used a dataset containing 83,287 medical check-up and treatment records obtained from 35,504 individuals in 5 fiscal years. The probit models were used in the study. Considering the possibility of endogeneity problems, different types of models were used. Results: We could not find evidence that a higher systolic BP increased the probability of undergoing HD treatment. However, diastolic BP increased the probability in most of the models. Taking antihypertensive drugs also increased the probability of undergoing HD treatment. Diabetes was another important risk factor. Conclusion: The results of this study did not support the new 2017 ACC/AHA Guideline. It is necessary to choose proper drugs and methods to reduce the risks of side effects. Limitations: The dataset was observatory, the data were obtained from just one medical society, and sample selection bias might exist.
Introduction
High blood pressure (BP) or hypertension is considered one of the most important health risk factors. The World Health Organization (WHO) [1] mentioned that "Worldwide, raised blood pressure is estimated to cause 7.5 million deaths, about 12.8% of the total of all deaths. This accounts for 57 million disability adjusted life years (DALYS) or 3.7% of total DALYS. Raised blood pressure is a major risk factor for coronary heart disease and ischemic as well as hemorrhagic stroke". WHO and the International Society of Hypertension (ISH) [2] estimated that hypertension is estimated to cause 4.5% of the current global disease burden. Gaziano et al. [3] also estimated that the global cost of suboptimal BP Centers for Disease Control and Prevention [6] also estimated that the cost of hypertension was $48.6 billion. In Japan, the medical expenditure on hypertension was 1.8 trillion yen in fiscal year 2016 [7] , and it is considered a very important disease. Furthermore, it has been reported that hypertension reduces quality of life [8] [9] and it has been suggested that the real cost of hypertension including indirect costs might be higher.
The distribution of BP is continuous, and several criteria of hypertension were proposed. For example, the Japanese Society of Hypertension (JSH) [10] and the Blood Pressure Association of United Kingdom [11] diagnosed hypertension if the systolic BP (SBP) was 140 mmHg or more or the diastolic BP (DBP) was 90 mmHg or over (hereafter, 140/90). The National Heart, Lung and Blood Institute of the United States [12] classified hypertension into Stage 1 (SBP of 140 -tively. Chung et al. [21] reported that the national weighted prevalence rates of brachial hypertension according to the 2017 guideline would be 40.7% in men and 30.7% in women, increasing by 18.8% and 9.4% in men and women, respectively, from that determined according to the previous criterion in Taiwan.
Marchesan and Spritzer [22] reported that the prevalence of systemic arterial hypertension among women with polycystic ovary syndrome was 65% according to the 2017 ACC/AHA Guideline and 26.6% according to the JNC7 criterion.
On the other hand, the European Society of Cardiology and the European Society of Hypertension (ESC/ESH) [23] , Hypertension Canada [24] [25] and the American Diabetes Association [26] maintained the diagnostic threshold of 140/90 mmHg for the general public in their 2018 guidelines. The Japanese Society of Hypertension (JSH) has been revising the 2014 Guidelines for the Management of Hypertension (JSH 2014 Guideline), and in their 2019 guideline declared that "We will not change the definition or category of hypertension because we think it appropriate to define hypertension as the level of BP at which the benefits of treatment unequivocally outweigh risks of treatment in the line of ESC/ESH guidelines" [27] . Moreover, the American Academy of Family Physicians (AAFP) [28] , an organization that initially adopted the 2017 ACC/AHA Guideline, declared that they would not follow the 2017 ACC/AHA Guideline and would use the previous guideline. The AAFP explained that systematic reviews of the new guideline had not been done, that the prevalence of hypertension among US adults would increase from 32% to 46%, and that substantial weight had been given to the Systolic Blood Pressure Intervention Trial (SPRINT)
Reviews of Previous Studies
Many studies of the relationships between BP and health conditions have been done, including the well-known, long-term Framingham Heart Study (FHS) [30] , which has been continuously conducted by Boston University and the National Heart, Lung, & Blood Institute since 1948 in Framingham, Massachusetts. As the initial cohort, 5209 males and females aged 30 -62 without clear signs or symptoms of HD were chosen. The study has found that male sex, age, cholesterol, SBP and diabetes are prediction factors of CVD over the course of 30 years.
The SPRINT [29] , weighted heavily in the 2017ACC/AHA Guideline, was a trial in which 9361 persons with SBP of 130 mmHg or higher and an increased CVD risk, but without diabetes, were randomly assigned into two groups. One group was the intensive treatment group of 4678 persons with an SBP target less than 120 mmHg and the other was the standard treatment group of 4683 persons. The enrollment period ran from November 2010 to March 2013, and the trial was terminated earlier than the planned period. The median follow-up period on August 20, 2015 was 3.26 years, and the planned average period was 5 years. The trial found lower rates of fatal and nonfatal major cardiovascular events and of death from any cause. In the trial, lifestyle modifications were encouraged. The average numbers of BP medications given to participants were 2.8 and 1.8, and the mean SBP values were 121.5 and 134.6 mmHg in the intensive treatment and standard treatment groups, respectively. However, the SPRINT was not a blinded, randomized clinical trial. The participants and doctors (or researchers) could easily know which groups the participants belonged to.
Therefore, we could not deny effects similar to the placebo effect [31] [32] . The rates of death from any cause were similar for the first two years, and the number of participants decreased after 3 years or more. Lowering BP with medications may cause adverse effects. The SPRINT research group themselves admitted that [29] "acute kidney injury, … were higher in the intensive-treatment group than in the standard-treatment group". With regard to SPRINT, also see Leung et al. [33] .
SPRINT used the same method used by the Action to Cardiovascular Risk in Diabetes (ACCORD) Study Group [34] . The ACCORD study involved 4733 persons with type 2 diabetes. The ACCORD study reported that lowering the SBP below 120 mmHg did not reduce the major CVD or death rates compared to the cases in which the SBP was lowered below 140 mmHg.
The Prospective Studies Collaboration [35] performed a meta-analysis using individual data for one million adults obtained from the results of 61 prospective studies. In this study, they analyzed 12.7 million person-years and reported 56,000 vascular mortalities including 12,000 due to stroke and 34,000 due to ischemic HD (IHD). They also reported that deaths due to IHD increased as SBP and DBP increased in all age cohorts (from 40 -49 to 80 -89).
Ettehad et al. [36] performed a meta-analysis using 123 studies selected from 11,428 studies that focused on lowering BP from January 1966 and July 2015. The total number of individuals included in the analysis was 613,815. They reported that treatments for lowering BP significantly reduced the major CVD risk and that lowering SBP by 10 mmHg reduced mortality rates from all causes by 13%.
Joffres et al. [37] analyzed BP using Canadian (Canadian Heart Health Survey (CHHS)) and US (NHANESIII) data. These data included 23,111 observations in Canada and 15,326 in the United States. They reported similar trends concerning age in both datasets, with prevalence rates of diabetes in the age range of 10 -74 of 20.1% in the NHANES and 21.1% in the CHHS, and about half of diabetes patients had hypertension and were managed poorly.
Rapsomaniki et al. [38] Muntner et al. [39] However, in their analysis, while some characteristics of the patients were considered, "obesity" was not. Ihum et al. [40] discussed the issues, particularly the optimal target BP, from an Asian perspective.
In Japan, a survey of "Nippon Data 2010" [41] performed using funds from the Ministry of Health, Labor and Welfare was done. In this survey, the BP levels of 2891 participants were recorded and the average SBP levels were 137.4 for males and 130.8 mmHg for females. In a national survey, SBP has been declining for 50 years for all ages and genders. However, for DBP, the same trend was observed for females but not males [42] . Fujiyoshi et al. [43] analyzed the relation between BP and CVD using a dataset of 63,309 individuals by cohorts based on age and gender. They reported 1944 CVD mortalities in 10.2 years and a positive relation between CVD and BP. Asayama et al. [44] Most studies mentioned that a higher SBP made the risk of CVD higher.
However, questions have arisen about the results of previous studies, as pointed out by Nawata, Sekizawa, and Kimura [47] . Biases such as publication, conflict of interest, and termination (or endpoint) biases might exist in these studies.
The selection criteria of the studies might also be problematic for meta-analysis.
Although the selection criteria should have been determined before the studies were done, they were in fact determined after the studies ended, which might cause another type of bias. For the cohort studies, the effects of individual characteristics other than BP could not be removed if the cohort interval was too large. For example, 10-year (or longer) age cohort intervals were often used.
Nawata et al. [48] found that SBP increased by about 5 mmHg with 10 years of increased age, and thus the 10-year age cohort interval might have been too large.
Sample-selection biases and the selection of explanatory variables were other important problems to be properly treated [49] .
More recently, Nawata and Kimura [49] [50] analyzed the total annual medical expenditures and results of BP measured using the power transformation 
Data and Methods

Data
Japan has a public health insurance system that requires all citizens to belong to some type of public health insurance organization. Most employees 40 years of age or older are required to undergo medical checkups once a year by law [51] , and family members can also undergo medical checkups on a voluntary basis.
The dataset was created with the cooperation of a health insurance society formed by a group of small corporations. All employees of the corporations and their family members are required to belong the health insurance society. The 
Probit Model
In many studies, including SPRINT, the Cox proportional hazard method [54] 
Models and Covariates
Covariates Used in the Analysis
We considered several different models, and the covariates used in this study were as follows ( 
Estimated Models
We first estimated the relation between undergoing HD treatment and the values of the covariates in the same fiscal year. Since taking antihypertensive drugs obviously affects the values of SBP and DBP, we considered two models given by:
Model A: Y + is a variable observed at t + 1. On the other hand, the covariates on the right-hand side are measured at the previous fiscal t. ( To avoid unnecessary complications, we eliminated the subscript t for covariates on the right-hand side of the equations. Since the data for fiscal year 2013 were not available, the 2014 and 2012 data are used for t + 1 and t when t = 2012.) Since individuals did not undergo HD treatment in fiscal year t, we can void the endogeneity problem.
Hereafter we refer to Model C and Model D as the predicting HD models. A total of 36 The estimates of other covariates were not significant in Model A and Model B.
Results of Estimation
The results of Model C and Model D are given in Table 4 . In these models, undergoing HD treatment was measured at t + 1 (i.e., 
Discussion
First, we considered the effects of SBP and DBP on HD. In all four models, the estimates of SDP were either negative or insignificant. On the other hand, all estimates of DBP were positive and significant at least at the 5% level in three models. Although previous studies such as the SPRINT and ACCORD trials mainly considered SBP to represent hypertension, the results of this paper suggest that DBP is a more important factor to be considered. To clarify the meaning of these results, we replaced SBP and DBP with BP_level = (SBP + DBP)/2
and BP_difference = SBP − DBP in Models A-D. We denoted these as Models A'-D'; BP_level represents the absolute level of BP, and BP_difference is the difference between SBP and DBP, which is important in sending blood through the body. The results of the estimation of BP_level and BP_difference are given in Table 5 . Since BP_level and BP_difference were obtained by linear transformations of SBP and DBP, the results of all of the other covariates were unchanged.
The estimates of BP_level were positive and significant at the 1% level in all models. The estimates of BP_difference were negative in all models and significant at the 1% level in Models A' and B'. In Model B', the absolute value of the estimate of BP_difference was almost twice as large as that of BP_level. These results strongly suggest that both SBP and DBP should be considered in the evaluation of BP. Lowing SBP is not sufficient, and lowering DBP is more important. Nawata, Sekizawa, and Kimura [47] suggested that taking antihypertensive drugs would reduce SBP by 9.17 mmHg. Using the same model, taking antihypertensive drugs would reduce DBP by 6.14 mmHg. (The results of the estimation are given in Table 6 1) The health conditions of individuals taking antihypertensive drugs were worse than those not taking antihypertensive drugs, and they were in the pre-stages of HD.
2) Individuals taking antihypertensive drugs went to hospitals or clinics more frequently than those not taking antihypertensive drugs. As a result, HD was more likely to be found earlier.
3) The antihypertensive drugs have rather negative side effects on HD which outweigh the benefits of the drugs.
K. Nawata et al. Various factors affecting the participants' health conditions were considered in our models. If the first hypothesis is correct, we missed some important factors that might affect HD, and it is necessary to identify such factors and add them to medical checkups. We cannot evaluate the second and third hypotheses K. Nawata et al.
precisely at the current stage and cannot reject the third hypothesis.
The major pharmacological classes of antihypertensive drugs used are [60] [61]
[62]: calcium channel blockers, angiotensin II receptor antagonists, angiotensin-converting enzyme inhibitors, diuretics, and β-blockers. In addition to these medicines, alpha-adrenergic receptor blockers and others (including vasodilators, centrally acting drugs, and renin inhibitors) are used based on the conditions of the patients. Every drug has side effects [63] . For the mechanism of action of the side effects, see the review work of Laurent [62] . It is necessary to choose the proper methods [64] and drugs to reduce the risks of side effects [61] [65]. These results suggested that the 2017 ACC/AHA Guideline was not supported. We could not deny the possibility that the negative side effects might be more significant than the benefits of the antihypertensive drugs. We need more detailed analyses using a larger dataset with a longer time-range to assess the benefits and negative side effects.
Most of the estimates of the other covariates had the expected signs. Although LDL cholesterol is referred to as "bad" cholesterol, higher LDL values lowered the probability of undergoing HD treatment. Also, although the reason is unknown, higher levels of urine sugar also reduced the probability of undergoing HD treatment. Smoking lowered the probability of undergoing HD treatment;
however, other negative effects of smoking were not analyzed in this paper. Age, gender, weight change of more than 3 kg within a year, and diabetes were significant in both the having and predicting HD models. Among these covariates, the estimates and t-values of Diabetes were very large in all models. Special care is necessary to prevent HD in individuals with these risk factors, especially those with diabetes. BMI, ALT, AST, walking faster than other people, not eating breakfast, and sleeping well were significant factors in the HD models. The estimation results of the predicting models suggested that AST and blood sugar levels might be important predicting factors, and that daily physical activities might reduce the probability of undergoing HD treatment in the next year. All fiscal year dummies were positive and significant in all models. This may reflect the fact that the number of months included in fiscal year 2016 was smaller than that in the other fiscal years.
Conclusion
In this study, the effects of BP and antihypertensive drugs on the probabilities of undergoing HD treatment were analyzed using the probit model. The data of The data were obtained with the cooperation of one health insurance society.
We first evaluated the probabilities of undergoing HD treatment in the same fiscal years using the two HD models. The estimates of SBP were negative in both HD models and significant in one model. On the other hand, estimates of DBP were positive in the HD models. The HD treatment might affect the values Health of the covariates, and an endogeneity problem might exist. To avoid this problem, we next evaluated individuals who were not undergoing HD treatment in fiscal year t and the probabilities that these individuals would undergo HD treatment in the next fiscal year, t + 1, with the two predicting HD models. The estimates of SBP become positive, but they were not significant. The estimates of DBP were positive and significant in one model. These results might imply that DBP was a more important risk factor than SBP. Levels of BP should be defined using both SBP and DBP (such as by using the average), and differences in SBP and DBP should also be considered. Therefore, previous studies that just focused on SBP, such as ACCORD and SPRINT, should be revised. We then evaluated the effects of hypertensive drugs. Surprisingly, taking hypertensive drugs made the probability of undergoing HD treatment higher. It is necessary to choose 
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By multiplying the conditional probabilities for all individuals, we get the partial likelihood, which is similar to the logit method,
By maximizing this function, we can obtain estimators. 
This means that we cannot use a simple Cox proportional hazard method when there exist time-dependent or time-varying variables that fluctuate rapidly over time.
